%0 Journal Article
%T Toll样受体4在淋巴瘤细胞株中的表达及其对细胞增殖和耐药的影响
%A 克晓燕
%A 张巍
%A 王晶
%A 闫新星
%J 肿瘤防治研究
%D 2016
%R 10.3971/j.issn.1000-8578.2016.06.001
%X 摘要 目的 探讨Toll样受体4（Toll-like receptor 4，TLR4）在人淋巴瘤细胞株中的表达及其对细胞增殖和耐药的影响。方法 采用RT-PCR、qPCR和Western blot检测8株淋巴瘤细胞株中TLR4 mRNA及蛋白的表达情况并筛选出TLR4高表达株，对高表达株进行基因测序以排除MyD88 L265P基因突变。将TLR4高标达细胞株分为空白对照组、TAK-242组、细菌脂多糖（lipopolysaccharides, LPS）组和LPS+TAK-242组，分别进行细胞增殖和阿霉素耐药实验。采用CCK-8试剂盒检测其增殖活性和细胞杀伤率，用Western blot法检测增殖细胞核抗原（proliferating cell nuclear antigen, PCNA）和P-糖蛋白（P-glycoprotein, P-gp）的变化。结果 8株淋巴瘤细胞株中TLR4 mRNA和蛋白广泛表达，其中Burkitt淋巴瘤细胞株Raji的表达水平最高。Raji细胞MyD88基因为野生型。与空白对照组相比，TAK-242和LPS+TAK-242组Raji细胞的增殖活性无明显改变（P=2.19, P=1.85），LPS组Raji细胞的增殖活性明显升高（P=0.016）， LPS组PCNA蛋白表达明显升高（P=0.009）。阿霉素在半数抑制浓度下各组杀伤率分别为：空白对照组（49.23±2.03）%、TAK-242组（51.41±1.12）%、LPS组（24.65±3.17）%、LPS+TAK-242组（41.17±2.69）%，可见LPS组细胞杀伤率明显降低（P=0.002）。P-gp蛋白表达明显升高（P=0.001）。结论 TLR4分子在淋巴瘤细胞株中广泛表达，尤以Burkitt淋巴瘤细胞株Raji最高，激活TLR4可以促使肿瘤细胞增殖和耐药，其机制可能与PCNA和P-gp的表达上调有关
%K A Case Report
%K Effect of Cisplatin Combined with Buzhong Yiqi Decoction on survivin Expression in Transplantation Tumor of Nude Mice with A549/DDP Cells
%K Current Research Status of NF-kappa B Related Molecular Pathway in Diffuse Large B Cell Lymphoma
%K Effects of FEN1 Overexpression on Biological Behaviors of Hepatocellular Carcinoma Cells and Prognosis of Patients
%K UGCG is Involved in Oxaliplatin Resistance Mechanism of Human Colon Cancer Through Regulating MDR1/P-gp Expression
%K Predictive Factors for Customizing Chemotherapy on Advanced Lung Adenocarcinoma
%K Bioinformatics Analysis of Genes Related to Multidrug Resistance in Ovarian Cancer
%K Knockdown of PKD1 Decreased Sensitivity of Human Salivary Gland Adenoid Cystic Carcinoma Cell Line ACC2 to Paclitaxel
%K Impact of miRNA-200c on Methotrexate Resistance of Non-small Cell Lung Cancer Cells A549
%K Clinical Characteristics and Prognosis of 123 Patients with Diffuse Large B-cell Lymphoma of Waldeyer’s Ring
%K Mechanism of Jinlong Capsule Reversing Paclitaxel Resistance of A549 Cells Investigated by System Biology Technology
%K miR-143/145 Cluster Regulate Multi-drug Resistance of Small Cell Lung Cancer
%U http://www.zlfzyj.com/CN/abstract/abstract8763.shtml